Convalescent plasma therapy / Institute of Liver and Biliary Sciences - LARVOL DELTA

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. (PubMed, An Acad Bras Cienc) - "However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups."

Journal • Infectious Disease • Novel Coronavirus Disease

An Exploratory Study of the Differences in Attitudes and Motives Regarding COVID-19 Plasma Donation. (PubMed, Acta Med Litu) - "Convalescent plasma donation during this time of grief and loss was considered a moral responsibility by voluntary donors. The impact of media was more highly perceived in voluntary plasma donors when compared to replacement donors."

Journal • Infectious Disease • Novel Coronavirus Disease • Psychiatry

Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). (PubMed, BMJ Open) - P3 | "Convalescent plasma with adequate antibody titres should be transfused in COVID-19 patients along with SMT in the initial 3 days of hospitalisation for better clinical outcomes."

Journal • Allergy • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • TNFA

[VIRTUAL] PROFILE OF SARS CoV2 INFECTION AMONG LIVER TRANSPLANT RECIPIENTS ACROSS ASIA PACIFIC (AASLD 2021) - P=N/A | "Any antiviral was received by 36%, convalescent plasma by 26% and immunomodulators like tocilizumab or bevacizumab in 13%. Compared to general population post-LT patients have an increased mortality due to COVID . Home based care could be feasible in only half of the patients ."

Clinical • Diabetes • Genetic Disorders • Hepatology • Hypertension • Immune Modulation • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Non-alcoholic Steatohepatitis • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Respiratory Diseases • Transplantation

Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors. (PubMed, Immun Inflamm Dis) - "Patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CCL2 • CD8 • CSF1 • IFNG • IL18 • IL6 • LEP • MIF • SAA1

Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 (clinicaltrials.gov) - P3; N=400; Completed; Sponsor: Institute of Liver and Biliary Sciences, India; Recruiting ➔ Completed; Trial completion date: May 2021 ➔ Dec 2020; Trial primary completion date: May 2021 ➔ Dec 2020

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Psychological assessment and lived experiences of recovered COVID-19 patients who presented for convalescent plasma donation. (PubMed, Transfus Clin Biol) - "Poor quality of life and social stigma during the recovery phase is prevalent in COVID-19 recovered patients, for which formulation of holistic support strategies are the need of the hour."

Clinical • Journal • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Psychiatry

Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 (clinicaltrials.gov) - P3; N=400; Recruiting; Sponsor: Institute of Liver and Biliary Sciences, India

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients (clinicaltrials.gov) - P2; N=29; Completed; Sponsor: Institute of Liver and Biliary Sciences, India; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: Institute of Liver and Biliary Sciences, India; N=20 ➔ 40

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease

Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients (clinicaltrials.gov) - P2; N=20; Recruiting; Sponsor: Institute of Liver and Biliary Sciences, India

Clinical • New P2 trial